Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Selnoflast
RO7486967 · 2 trials · 2 indications
hsCRP=high-sensitivity C-reactive protein.
| Arm | Type | Description |
|---|---|---|
| Selnoflast | EXPERIMENTAL | Participants will receive selnoflast, orally (PO), twice a day (BID) for 12 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo, PO, BID for 12 weeks. |
| RO7486967 Arm | EXPERIMENTAL | Participants will receive RO07486967 for approximately 28 days with 14 days of follow up after the last dose. |
| Name | Type | Description |
|---|---|---|
| Selnoflast | DRUG | Selnoflast will be administered as per the schedule specified in the respective arm. |
| Placebo | DRUG | Placebo will be administered as per the schedule specified in the respective arm. |
| RO7486967 | DRUG | For up to approximately 28 days |
Inclusion Criteria: * Confirmed evidence of atherosclerosis * Left or right carotid TBR ≥ 1.8 or aorta TBR ≥ 2.0 on centrally-assessed 18F-fluorodeoxyglucose-Positron Emission Tomography (18F-FDG-PET) scan * Stable treatment of atherosclerosis through the use of SOC medications or revascularization...
Top 15 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| Bayer | BAYRY | 4 | PHASE3 | bemdaneprocel, AB-1005 |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Eli Lilly and Company | LLY | 4 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| Serina Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7568282 |
| Merck & Co., Inc. | MRK | 1 | EARLY_PHASE1 | MK-0947 |
RO7486967 is an investigational small molecule drug being developed by Roche Holding AG for Parkinson disease. It is in Phase 1 clinical development and has been studied in a single completed trial in participants with early idiopathic Parkinson's disease. It is not an approved therapy.
RO7486967 is being studied for the treatment of early idiopathic Parkinson's disease. The Phase 1 trial enrolled participants aged 40 years and older with that condition, and it was biomarker selected, meaning enrollment was tied to a biomarker. It is investigational and has not been approved for any use.
RO7486967 is developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program studying the compound in Parkinson disease.
RO7486967 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and is not approved by the FDA for Parkinson disease or any other indication.
RO7486967 has been evaluated in one Phase 1 trial, NCT05924243, titled a study of its safety, tolerability, pharmacokinetics and pharmacodynamics in participants with early idiopathic Parkinson's disease. The trial enrolled 60 participants across the United States, Netherlands and United Kingdom, was randomized, double blind and placebo controlled, and is completed.
RO7486967 is a small molecule developed for Parkinson disease, and the Phase 1 trial NCT05924243 assessed its pharmacokinetics and pharmacodynamics in participants with early idiopathic Parkinson's disease. The study was biomarker selected, indicating a biomarker-guided approach to the trial population.